Company news
Dare Bioscience, Inc. (NASDAQ:DARE) news
Every Dare Bioscience, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
September 11, 2026
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
August 31, 2026
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
August 27, 2026
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
August 26, 2026
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
August 18, 2026
Dare Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
August 17, 2026
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
August 14, 2026
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
August 13, 2026
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
July 28, 2026
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
July 20, 2026
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
July 9, 2026
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
July 1, 2026
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” ...
June 25, 2026
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
June 4, 2026
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV I...
May 26, 2026
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-A...
May 18, 2026
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
May 7, 2026
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
March 26, 2026
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
March 20, 2026
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
March 16, 2026
Daré Bioscience Participates in Virtual Investor “What This Means” Segment
March 12, 2026
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV...
February 23, 2026
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women
February 11, 2026
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins C...
December 10, 2025
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset ...
December 1, 2025
Dare Bioscience Receives $3.6 Million in Additional Grant Funding
November 25, 2025
Daré Bioscience Receives $3.6 Million in Additional Grant Funding
November 24, 2025
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Dare Bioscience Highlights Commercial Launch Readiness for DARE to PLAY Sildenafil Cream, November 17th Webinar to Feature Leading Clinic...
November 12, 2025
Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clini...
November 11, 2025
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
November 6, 2025
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
November 3, 2025
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting ...
October 6, 2025
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting ...
October 6, 2025
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
September 24, 2025
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
August 7, 2025
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
July 29, 2025
UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
July 21, 2025
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
July 21, 2025
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
July 14, 2025
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Deliver...
July 11, 2025
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
June 12, 2025
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
June 4, 2025
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
May 13, 2025
Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025
May 6, 2025
Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women...
April 23, 2025
Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to...
April 7, 2025
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
March 31, 2025